Rapport Therapeutics, Inc. RAPP Preclinical Programs External Expenses — Research And Development Expense

Other product segments

Similar metrics at other companies

MPLTPreclinical Program — Research And Development Expense

$5.52M-9.2%

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

ABSIExternal preclinical and clinical development — R&D

$4.29M+59.7%

LBR

LBRXPreclinical — Direct Research And Development Expenses

$32.25K-93.0%

ZYMEExpense for other preclinical and research programs — R&D

$7.26M+19.6%

LBR

LBRXPreclinical And Other Direct Expenses — Direct Research And Development Expenses

$501K—

Questions, answered.

What is Rapport Therapeutics, Inc.'s preclinical programs external expenses — research and development expense?

Rapport Therapeutics, Inc. (RAPP) reported preclinical programs external expenses — research and development expense of $4.29M in Q1 2026.

How has Rapport Therapeutics, Inc.'s preclinical programs external expenses — research and development expense changed year-over-year?

Rapport Therapeutics, Inc.'s preclinical programs external expenses — research and development expense increased by 32.1% year-over-year, from $3.25M to $4.29M.

What is the long-term trend for Rapport Therapeutics, Inc.'s preclinical programs external expenses — research and development expense?

Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s preclinical programs external expenses — research and development expense has grown at a 61.7% compound annual growth rate (CAGR), from $6.34M to $16.57M.

What does preclinical programs external expenses — research and development expense mean?

This metric represents the external costs incurred for research and development activities specifically associated with the company's preclinical-stage drug discovery programs. It captures third-party expenditures such as contract research organization fees, laboratory services, and materials required to advance therapeutic candidates toward clinical trials. Monitoring this expense provides insight into the capital intensity and investment pace of the company's early-stage pipeline development.